Nutrition management guideline for maple syrup urine disease: An evidence- and consensus-based approach
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
In an effort to increase harmonization of care and enable outcome studies, the Genetic Metabolic Dietitians International (GMDI) and the Southeast Regional Newborn Screening and Genetics Collaborative (SERC) are partnering to develop nutrition management guidelines for inherited metabolic disorders (IMD) using a model combining both evidence- and consensus-based methodology. The first guideline to be completed is for maple syrup urine disease (MSUD). This report describes the methodology used in its development: formulation of five research questions; review, critical appraisal and abstraction of peer-reviewed studies and unpublished practice literature; and expert input through Delphi surveys and a nominal group process. This report includes the summary statements for each research question and the nutrition management recommendations they generated. Each recommendation is followed by a standardized rating based on the strength of the evidence and consensus used. The application of technology to build the infrastructure for this project allowed transparency during development of this guideline and will be a foundation for future guidelines. Online open access of the full, published guideline allows utilization by health care providers, researchers, and collaborators who advise, advocate and care for individuals with MSUD and their families. There will be future updates as warranted by developments in research and clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Epidemiology of mucopolysaccharidoses
Khan, S. A., Peracha, H., Ballhausen, D., Wiesbauer, A., Rohrbach, M., Gautschi, M., Mason, R. W., Giugliani, R., Suzuki, Y., Orii, K. E., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.05.016 · Cited by 1,094
Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients
Morton, D. H., Strauss, K. A., Robinson, D. L., Puffenberger, E. G., & Kelley, R. I. (2002) · Pediatrics · doi:10.1542/peds.109.6.999 · Cited by 326 · cited 1×
“At diagnosis or any time there is a risk of metabolic decompensation during trauma, surgery, illness or inappropriate dietary intake, the goals are to: closely monitor biochemical and clinical status [14–17]; prevent catabolism and the accumulation of endogenous BCAA and BCKA; and provide adequate BCAA-free exogenous…”
BackgroundMaple syrup urine disease (branched-chain ketoaciduria)
Chuang, D. (2001) · Medical Entomology and Zoology · Cited by 253
Strauss, K. A., Wardley, B., Robinson, D., Hendrickson, C., Rider, N. L., Puffenberger, E. G., Shelmer, D., Moser, A. B., & Morton, D. H. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.12.007 · Cited by 196 · cited 4×
“Non-acutely ill individuals can often be managed with a “sick day” guideline that provides detailed instruction for preventing catabolism and monitoring clinical status [18,20,24].”
BackgroundInfluentialKaye, C. I., & and the Committee on Genetics (2006) · Pediatrics · doi:10.1542/peds.2006-1783 · Cited by 184
THIAMINE-RESPONSIVE MAPLE-SYRUP-URINE DISEASE
Scriver, C. R., Clow, C. L., Mackenzie, S., & Delvin, E. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91041-5 · Cited by 173
Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease
Zinnanti, W. J., Lazovic, J., Griffin, K., Skvorak, K. J., Paul, H. S., Homanics, G. E., Bewley, M. C., Cheng, K. C., LaNoue, K. F., & Flanagan, J. M. (2008) · Brain · doi:10.1093/brain/awp024 · Cited by 157 · cited 1×
“These include, but not limited to, the use of norleucine [65], antioxidants [66,67], hepatocyte transplantation [68], sodium phenylbutyrate [69] and carnitine [70].”
BackgroundElective Liver Transplantation for the Treatment of Classical Maple Syrup Urine Disease
Strauss, K. A., Mazariegos, G. V., Sindhi, R. K., Squires, R., Finegold, D. N., Vockley, J., Robinson, D. L., Hendrickson, C., Virji, M. A., Cropcho, L. J., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01209.x · Cited by 130 · cited 2×
“To be candidates for liver transplantation, individuals should be in good metabolic control through dietary management of their BCAA [54].”
BackgroundProfiling of oxidative stress in patients with inborn errors of metabolism
Guire, P. J. M., Parikh, A. G., & Díaz, G. A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.06.007 · Cited by 125 · cited 1×
“These include, but not limited to, the use of norleucine [65], antioxidants [66,67], hepatocyte transplantation [68], sodium phenylbutyrate [69] and carnitine [70].”
BackgroundTreacy, E. P., Clow, C., Reade, T. R., Chitayat, D. A., Mamer, O., & Scriver, C. R. (1991) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01800354 · Cited by 117 · cited 1×
“[29] [30] [31] [32] [33] [31] [32] [33] [20] [34] [35] 28”
MAPLE SYRUP URINE DISEASE: BRANCHED-CHAIN KETO-ACIDURIA
Dancis, J., Levitz, M., & Westall, R. G. (1960) · PEDIATRICS · doi:10.1542/peds.25.1.72 · Cited by 111
Phenylbutyrate therapy for maple syrup urine disease
Brunetti‐Pierri, N., Lanpher, B. C., Erez, A., Ananieva, E. A., Islam, M. M., Marini, J. C., Sun, Q., Yu, C., Hegde, M., Li, J., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq507 · Cited by 102 · cited 1×
“These include, but not limited to, the use of norleucine [65], antioxidants [66,67], hepatocyte transplantation [68], sodium phenylbutyrate [69] and carnitine [70].”
BackgroundDysmyelination in the brain of adolescents and young adults with maple syrup urine disease
SCHONBERGER, S. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.01.016 · Cited by 101 · cited 2×
“Elevated LEU concentrations are most often associated with abnormal brain morphology [29,30] and cognitive impairment [31–33]; and impact on social and psychomotor function varies [31–33].”
BackgroundHoffmann, B., Helbling, C., Schadewaldt, P., & Wendel, U. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000190571.60385.34 · Cited by 99 · cited 1×
“[29] [30] [31] [32] [33] [31] [32] [33] [20] [34] [35] 28”
(2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50245-1 · Cited by 92
Arnold, G. L., Koeberl, D. D., Matern, D., Barshop, B. A., Braverman, N., Burton, B. K., Cederbaum, S. D., Fiegenbaum, A., Garganta, C. L., Gibson, J. B., et al. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.11.002 · Cited by 72 · cited 1×
“Treatment recommendations and guidelines are currently published for a number of disorders but often they rely on either consensus and expert opinion [62] or literature review [63].”
BackgroundLiver transplantation in maple syrup urine disease
Wendel, U., Saudubray, J., Bodner, A., & Schadewaldt, P. (1999) · European Journal of Pediatrics · doi:10.1007/pl00014324 · Cited by 71 · cited 1×
“[12] [53] [54] [55] [56] [57] [58] [59] 54”
Chuang, J. L., Wynn, R., Moss, C., Song, J.-L., Li, J., Awad, N., Mandel, H., & Chuang, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313879200 · Cited by 71
Molecular Phenotypes in Cultured Maple Syrup Urine Disease Cells
Fisher, C., Chuang, J. L., Griffin, T. A., Lau, K. S., Cox, R. P., & Chuang, D. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94087-1 · Cited by 71
In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease
Mescka, C. P., Moraes, T. B., Rosa, A. P., Mazzola, P. N., Piccoli, B. L., Jacques, C. E. D., Dalazen, G. R., Coelho, J. G., Cortes, M. X., Terra, M., et al. (2011) · Metabolic Brain Disease · doi:10.1007/s11011-011-9238-x · Cited by 71 · cited 1×
“These include, but not limited to, the use of norleucine [65], antioxidants [66,67], hepatocyte transplantation [68], sodium phenylbutyrate [69] and carnitine [70].”
BackgroundBranched-chain ketoacyl dehydrogenase deficiency: Maple syrup disease
Strauss, K. A., & Morton, D. H. (2003) · Current Treatment Options in Neurology · doi:10.1007/s11940-003-0039-3 · Cited by 70 · cited 2×
“The goal of dietary BCAA restriction for the individual with MSUD is to achieve and maintain plasma BCAA concentrations as close to normal as possible while preventing and correcting BCAA deficiencies [20,28].”
BackgroundNutrition Management of Patients With Inherited Metabolic Disorders
Acosta, P. B. (2009) · Cited by 69
Puckett, R. L., Lorey, F., Rinaldo, P., Lipson, M. H., Matern, D., Sowa, M., Levine, S., Chang, R. C., Wang, R. Y., & Abdenur, J. E. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.11.010 · Cited by 68 · cited 1×
“Although there is the possibility of false positives due to generalized aminoacidemia, or hydroxyprolinemia [8] and false negatives for milder variants of MSUD [9] rapid follow up of positive newborn screening reports should result in fewer infants demonstrating the severe clinical symptoms in the newborn period [10].”
BackgroundNellis, M. M., Kasinski, A. L., Carlson, M. D., Allen, R. J., Schaefer, A. M., Schwartz, E. M., & Danner, D. J. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00144-6 · Cited by 67 · cited 2×
“Mutation analysis and enzymatic testing, although not necessary for diagnosis, may help predict severity of the disorder or thiamin responsiveness [5].”
BackgroundBerry, G. T., Heidenreich, R. A., Kaplan, P. B., Levine, F., Mazur, A., Palmieri, M. J., Yudkoff, M., & Segal, S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240307 · Cited by 58 · cited 1×
“At diagnosis or any time there is a risk of metabolic decompensation during trauma, surgery, illness or inappropriate dietary intake, the goals are to: closely monitor biochemical and clinical status [14–17]; prevent catabolism and the accumulation of endogenous BCAA and BCKA; and provide adequate BCAA-free exogenous…”
BackgroundShah, N. P. (2007) · Hematology · doi:10.1182/asheducation-2007.1.371 · Cited by 54
Case reports of successful pregnancy in women with maple syrup urine disease and propionic acidemia
Calcar, S. C. V., Harding, C. O., Davidson, S. R., Barness, L. A., & Wolff, J. A. (1992) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320440523 · Cited by 53 · cited 3×
“Supplemental vitamins andminerals may be needed for those nutrients not adequate in themedical food consumed [12,50].”
BackgroundMaple syrup urine disease (MSUD)—Clinical profile of 47 Filipino patients
Lee, J. Y., Chiong, M. A. D., Estrada, S. C., la Paz, E. M. C., Silao, C. L. T., & Padilla, C. D. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0859-0 · Cited by 48 · cited 1×
“[10] [14] [15] [16] [17] [18] [19] [20] [21] [10] [14] [16] [17] [18] [19] [20] [21] [22] [23] [14] [17] [20] [22] [10] [14] [15] [16] [17] [20] [21] [22] [23] [24] [10] [14] [15] [17] [19] [20] [21] [24] [25] [26] [5] [10] [14] [16] [17] [18] [19] [20] [21] [23] [24] [27] [18] [20] [24]”
Thiamine‐responsive inborn errors of metabolism
Durán, M., & Wadman, S. K. (1985) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01800663 · Cited by 45 · cited 1×
“[6] [40] [41] [42] [43] [44] [45] [2] [46] [47] 44 [6] [21] [42] [48]”
MacDonald, A., Depondt, E., Evans, S., Daly, A., Hendriksz, C. J., Chakrapani, A., & Saudubray, J. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0332-x · Cited by 38 · cited 1×
“[10] [14] [15] [16] [17] [18] [19] [20] [21] [10] [14] [16] [17] [18] [19] [20] [21] [22] [23] [14] [17] [20] [22] [10] [14] [15] [16] [17] [20] [21] [22] [23] [24] [10] [14] [15] [17] [19] [20] [21] [24] [25] [26] [5] [10] [14] [16] [17] [18] [19] [20] [21] [23] [24] [27] [18] [20] [24]”
Pregnancy issues in inherited metabolic disorders
Lee, P. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-0252-1 · Cited by 36 · cited 1×
“intake is not adequate [52].”
Thiamine Response in Maple Syrup Urine Disease
Fernhoff, P. M., Lubitz, D. S., Danner, D. J., Dembure, P. P., Schwartz, H. P., Hillman, R. E., Bier, D. M., & Elsas, L. J. (1985) · Pediatric Research · doi:10.1203/00006450-198510000-00012 · Cited by 35 · cited 1×
“This response is apparent within one month with a dosage of 50–200 mg/day [44].”
BackgroundScaini, G., Teodorak, B. P., Jeremias, I. C., Morais, M. O. D. S., Mina, F., Dominguini, D., Pescador, B., Comim, C. M., Schuck, P. F., Ferreira, G. C., et al. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.03.004 · Cited by 34 · cited 1×
“These include, but not limited to, the use of norleucine [65], antioxidants [66,67], hepatocyte transplantation [68], sodium phenylbutyrate [69] and carnitine [70].”
BackgroundBodner-Leidecker, A., Wendel, U., Saudubray, J., & Schadewaldt, P. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1026708618507 · Cited by 34
Skvorak, K. J., Hager, E. J., Arning, E., Bottiglieri, T., Paul, H. S., Strom, S. C., Homanics, G. E., Sun, Q., Jansen, E. E. W., Jakobs, C., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.006 · Cited by 31 · cited 1×
“These include, but not limited to, the use of norleucine [65], antioxidants [66,67], hepatocyte transplantation [68], sodium phenylbutyrate [69] and carnitine [70].”
BackgroundDanner, D. J., Wheeler, F. B., Lemmon, S. K., & Elsas, L. J. (1978) · Pediatric Research · doi:10.1203/00006450-197803000-00016 · Cited by 27 · cited 1×
“[6] [40] [41] [42] [43] [44] [45] [2] [46] [47] 44 [6] [21] [42] [48]”
Singh, R. H., Rohr, F., & Splett, P. L. (2011) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2011.01807.x · Cited by 24 · cited 4×
“The process, created for this project, was adapted from the Academy of Nutrition and Dietetics [11] with the addition of specific techniques to draw on the expertise from clinical practice to provide information where published research is lacking [1].”
MethodInfluentialSelf-citationNeuropsychometric outcome predictors for adults with maple syrup urine disease
le Roux, C. W., Murphy, E., Hallam, P., Lilburn, M. F., Orlowska, D., & Lee, P. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0223-1 · Cited by 22 · cited 1×
“Although relaxing dietary BCAA restriction in adolescents and adults has been reported in case studies and postulated to improve quality of life [29,30,36], this practice poses a risk of adverse outcomes [30] and has not been rigorously or objectively evaluated.”
BackgroundTörnqvist, K., & Tornqvist, H. E. (1996) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.1996.tb00386.x · Cited by 10 · cited 1×
“Low plasma BCAA, particularly ILE and to a lesser extent VAL, results in severe but reversible epithelial damage to the skin, eye and gastrointestinal tract [20,34,35].”
Background
Cited by
Goyanes, A., Madla, C. M., Umerji, A., Duran Piñeiro, G., Giraldez Montero, J. M., Lamas Diaz, M. J., Gonzalez Barcia, M., Taherali, F., Sánchez-Pintos, P., Couce, M.-L., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118497 · Cited by 292
Maple syrup urine disease: mechanisms and management
Blackburn, P., Gass, J., Pinto e Vairo, F., Farnham, K., Atwal, H., Macklin, S., Klee, E., & Atwal, P. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s125962 · Cited by 280
“, dialysis, hemofiltration, parenteral nutrition, and/or tube feedings).(40) Acute dietary treatment needs to be aggressive and include sufficient energy (up to 150% of the normal energy consumption), based on BCAA-free formula and fluid administration (up to 150 mL/kg).”
BackgroundMethodInfluentialO'Reilly, D., Crushell, E., Hughes, J., Ryan, S., Rogers, Y., Borovickova, I., Mayne, P., Riordan, M., Awan, A., Carson, K., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12337 · Cited by 24
“A key approach in our Centre is towards early diagnosis and emergency treatment with close monitoring and multidisciplinary team (MDT) management for our MSUD patients, with target leucine levels as close to normal as possible with <400 μM/L as acceptable upper limit, ideally 100 to 300 μM/L.(23,24) Growth during chil…”
Metadata
- Authors
- Frazier, D. M., Allgeier, C., Homer, C., Marriage, B. J., Ogata, B., Rohr, F., Splett, P. L., Stembridge, A., & Singh, R. H.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 112
- Issue
- 3
- Pages
- 210-217
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2003926893
- Cited by
- 194
- References
- 40
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.